Review

Current management of gynecologic cancer in pregnancy

Iavazzo et al. Gynecologic cancer in pregnancy

Christos Iavazzo¹, Evelyn Eleni Minis², Ioannis D. Gkegkes³

¹Department of Gynecological Oncology, Metaxa Cancer Hospital, Piraeus, Greece
²Department of Surgery, General Hospital of Attica “KAT”, Athens, Greece

*Corresponding author: Christos Iavazzo
Department of Gynecological Oncology, Metaxa Cancer Hospital, Piraeus, Greece
E-mail: christosiavazzo@hotmail.com

DOI: 10.4274/jtgga.2018.0044

Received: 9 April, 2018
Accepted: 23 April, 2018

Abstract
Cancer during pregnancy is a particularly challenging complication. The incidence has increased in recent years due to childbearing at an advanced maternal age due to career choices and/or the development of reproductive technology. Approximately two thirds of cancer cases during pregnancy are comprised of invasive cervical cancers and breast cancer. Cancer during gestation is characterized by a need for specialized treatment due to major changes in the hormonal profile (estrogen-progesterone), metabolism (enhancement of anabolism), hemodynamic changes (hyperdynamic circulation), immunologic changes (cell mediated and humoral immunity), increased angiogenesis (increased blood flow towards the uterus). Moreover, the management of such patients is based on the trimester of pregnancy, type and stage of cancer and informed consent of the mother based on her wishes. The optimal treatment of cancer during pregnancy remains elusive, as there are limited data from retrospective studies with small samples. As a result, it is crucial that data regarding survival of the women and long-term follow up of the children from different cancer centres and registries be shared. This need is dictated by the fact that the incidence of cancer during pregnancy will continue to rise as child-bearing age continues to increase. (J Turk Ger Gynecol Assoc)

Keywords: gynecologic cancer; pregnancy; breast cancer; endometrial cancer; vulvar cancer; cervical cancer

Introduction
The incidence of cancer during pregnancy is between 1/1,000-1/1,500 gestations (1). Importantly, the incidence has increased in recent years due to childbearing at an advanced maternal age due to career choices and/or the development of reproductive technology. Approximately one third of cancer cases during pregnancy are comprised of invasive cervical cancers, another third of hematologic malignancies (lymphoma, leukemia), while the remaining third is mostly breast cancer (2). Cancer during gestation is characterized by a need for specialized treatment due to major changes in the hormonal profile (estrogen-progesterone), metabolism (enhancement of anabolism), hemodynamic changes (hyperdynamic circulation), immunologic changes (cell mediated and humoral immunity), increased angiogenesis (increased blood flow towards the uterus) (3). Moreover, the management of such patients is based on the trimester of pregnancy, type and stage of cancer and informed consent of the mother based on her wishes.

The aim of our narrative review was to discuss the current management of pregnant women who are diagnosed with cancer based on the available current literature.

Methods
Data Sources
An extensive electronic search was performed in PubMed (02/04/2018) and Scopus (02/04/2018). The adopted search strategy included the combination of the following keywords: cancer/carcinoma and/or pregnancy/gestation and management/treatment. In order to retrieve additional studies, the references of the included studies were also searched. Studies written in languages other than English were not included. The literature search had a limitation at the search range, only studies written after 1990 were considered eligible for this review. Eighteen studies were
eligible to be included in our review. Studies reporting data on management of cancer patients during pregnancy were regarded as eligible for this review. Abstracts, conference papers, book chapters, animal studies, commentaries, editorials as well as review articles were excluded from this review.

**Breast cancer in pregnancy**

Breast cancer is thought to be associated with gestation if it is diagnosed during or within one year of pregnancy. The incidence is 1/3000 gestations, while the average age in which it presents is 32-38 years (4). Importantly, it is shown that the prognosis is worse if diagnosis is made during lactation. The physiologic changes in the morphology of the mammary glands (engorgement of breast) during pregnancy contribute to delayed diagnosis. Cancer during gestation can be diagnosed by mammogram, however the false negative rate is high (around 25%) due to the increased density of the breast. For this reason, a biopsy of any palpable mass is essential to achieve early diagnosis. The level of radiation in diagnostic mammography is too low to harm the embryo. In addition, U/S guided biopsy is of paramount importance for diagnosis. Genetics play a major role, especially in BRCA1 and BRCA2 carriers. Regarding treatment, the literature does not suggest a better prognosis following termination of pregnancy (5, 6). Treatment is the same as in patients that are not pregnant. Small tumors are treated by lumpectomy, while larger tumors are managed by modified radical mastectomy and axillary lymph node dissection. In recent years the role of the sentinel lymph node has also been under consideration in order to minimize the extent of dissection. According to Balaya et al, the blue dye injection has a theoretical 2% of anaphylactic shock. However, Tc99m injection at a dose of 12.1-18.5 mBq is safe for the fetus and the obstetric outcome (7). Adjuvant chemotherapy can be initiated after 16 weeks gestation, following the completion of organogenesis, while radiation is delayed until after delivery, despite evidence that radiation of the axilla or chest could be safe after the 1st trimester (8, 9). External beam radiation can be used whenever fetus can be exposed to secondary radiation due to head leakage, scatter from the machine and scatter produced inside the patient woman (10). Appropriate selection of irradiation parameters and different shielding devises can minimise the risk. It seems that overall survival of patients with breast cancer diagnosed during pregnancy is worse compared to prior pregnancy controls as principal result of a possible delayed diagnosis. The 5-year survival depends on cancer stage ranging from 85% on stage I down to 5% on stage IV (9).

**Vulvar and vaginal pre-invasive and invasive lesions**

Warts and intraepithelial lesions of the squamous epithelium (SIL) tend to increase in size during pregnancy. In most cases no treatment is recommended unless the lesions are symptomatic (11). These lesions regress following delivery. Alternative forms of treatment are imiquimod (Aldara®), 5-FU, trichloroacetic acid, podophyllin, removal by laser ablation, surgical removal, LEEP procedure (loop electrosurgical excision procedure) or cryotherapy (12). Diagnosis of vulvar cancer during pregnancy is especially rare as it is more common in postmenopausal women, with the average age of diagnosis being 60-70 years. However, the literature describes 37 cases of vulvar cancer diagnosed during pregnancy (13, 14). A systematic review of the literature that the mean age during diagnosis was 30.7 years old, three out of four women were diagnosed with vulvar mass/swelling and more than 50% during second trimester. Squamous histology was found in the majority of the cases (13). Surgical removal is recommended (wide excision with unilateral or bilateral inguinal lymph node dissection) during the second or third trimester, more commonly before 36 weeks gestation, in order for the wound to heal prior to delivery. Importantly, hemostasis is often challenging due to increased vascularity. The majority of cases result in excellent pregnancy outcomes, however delayed diagnosis and management affect disease free and overall survival (13). The management of vulvar cancer in pregnancy does not differ from that in a non-pregnant patient and consists of radical vulvectomy and groin lymph node dissection when the depth of invasion is >1mm. A systematic review concluded that in 72% of cases, the preferred procedure by gynecologic oncologists is radical vulvectomy, carried out usually post-partum (59.3%). Less commonly the procedure may also be performed during the second trimester, while only one patient was operated in the first trimester (15). The majority of patients (95%) underwent bilateral inguinal femoral node dissection in the postpartum period. Regarding sentinel node biopsy with 99mTC (no blue dye), only one such case has been reported on, in which there was no harm to the fetus reported (16).

**Pre-invasive and invasive lesions of the cervix during pregnancy**

The prevalence of HPV in women aged from 14 to 59 years old is 42.5% (17). Regarding pre-invasive lesions of the cervix, 2-6.5% of cervical intraepithelial neoplasia (CIN) / squamous intraepithelial lesion (SIL) cases present during gestation, while 10-50 cases of cancer have been reported per 100,000 gestations (18). In addition, 1.9% of microinvasive cancer cases are diagnosed during pregnancy (19). The Pap smear as well as colposcopy should be performed as routine workup for diagnosis of pre-invasive lesions during pregnancy. During pregnancy hypertrophy of the glandular epithelium is observed, resulting in the translocation of the transformation zone to the ectocervix. In addition the increased vascularity, engorged cervix and glandular hyperplasia make diagnosis through cytology and colposcopy challenging. There is a characteristic purplish hue due to the increased vascularity as well as a
hypertrophy of the glandular epithelium and edema of the cervix. However, indications for colposcopy remain the same in pregnancy.

According to the literature, 0.4-10% of CIN II-III cases develop into invasive cancer (20). Conversely 47-74% of cases regress (20-22). A conservative approach of pre-invasive lesions is necessary in order to avoid complications such as preterm labor. As a result, the patient should be monitored every 6-8 weeks, colposcopy should be performed every 12 weeks, while the patient should be reassessed 12 weeks after delivery (23, 24). Treatment should be delayed until after delivery. During pregnancy, cone biopsy is recommended in patients that are suspected to have invasive cancer. However, an Israeli study suggested that LEEP procedure during the first 15 weeks of gestation is safe and reconsideration of guidelines was proposed (25). More specifically a non-satisfactory colposcopy / Pap smear, adenocarcinoma in situ and microinvasive cancer are indications for a cone biopsy (24). Cone biopsy is performed during the 14-20th week of gestation. Postoperative complications include miscarriage (5%) and bleeding (9%) (24). Diagnostic workup includes MRI scan of the abdomen (as use of CT scan is limited during pregnancy), chest X-ray, CEA levels, cystoscopy and rectal colonoscopy in order to achieve a complete staging. Counseling by a gynecologist oncologist is also recommended.

The appropriate treatment is often individualized and depends on whether the patient wishes to conserve her fertility, staging and gestational age. More specifically continuation of pregnancy until fetal lung maturity is achieved, is suggested in stage I disease at 20 weeks gestation and over. Regarding Stage IA1 cone biopsy is preferred with no additional treatment required (1.2% risk of lymph node metastases), with vaginal delivery being the preferred mode of delivery (23). Regarding stage IA2, cone biopsy combined with pelvic lymph node dissection during pregnancy and excision of the cervix immediately following delivery is recommended (19). With regards to stage IA2 and IIA, a c-section followed by radical hysterectomy and lymph node dissection is recommended. Often, transposition of the ovaries out of the range of radiation, in order to conserve ovarian function, is considered (26).

In a recent study by Vercellino et al. laparoscopic pelvic lymphadenectomy was performed on 32 patients in their first and second trimester (27). The median number of excised lymph nodes was 14 (8-57), while it was concluded that the optimal time for operation is prior to 22-24 weeks gestation. In addition, there were no intraoperative complications reported on.

Radiation is first choice in stage IIB or above (26). Prognosis of cervical cancer is not affected by gestation. 20% of cases are diagnosed due to post-coital bleeding, while 63% do not present with an abnormal Pap smear (19). Mortality is low, while survival rate is up to 95%. In a recent cohort study by Bigelow et al, a planned c-section was the preferred delivery method in cases of confirmed malignancy, while vaginal deliveries performed on patients with microinvasive cancer or an unconfirmed diagnosis were not shown to affect disease progression and survival or cause perinatal complications (28). Despite these results, the authors concluded that elective c-section could be suggested as the optimal management, in view of potential local recurrence and distal metastasis (29-33).

The same study reported that survival was not affected in cases were surgical intervention was performed in the post-partum period, reporting 5-year survival rates comparable to those of large-population studies (34). Pregnant patients were not found to have any difference regarding oncologic outcome, despite the considerable delay between diagnosis and intervention. Thus, the authors suggested delaying delivery to a gestational age of 37-39 weeks, especially considering the significant morbidity and mortality associated with preterm delivery (35-38). Conversely, a number of recent publications regarding cervical cancer in pregnancy suggest preterm delivery in order to initialize treatment earlier (19, 35, 39). In addition, in a study by Xia et al, delayed intervention was associated with decreased survival. However, this study group included a significant number of patients with malignant disease >4cm and aggressive histopathology (33). Similar findings have not been reported by other studies (40-42).

Regarding chemotherapy, a platinum-based cisplatin is the preferred agent (50-100mg/m²) (19). This may be as a monotherapy, or combined with paclitaxel (175 mg/m²), bleomycin, vincristine, 5-fluorouracil or vincristine and bleomycin. Another combination that has been suggested is paclitaxel and carboplatin (43, 44). It has been reported that chemotherapy should be administered every three weeks, while delivery should be scheduled at a minimum of three weeks following the final dose, in order to minimize risks of perinatal complications (45, 46). Regarding intrauterine complications, it is suggested that chemotherapy should not be administered during the first trimester, due to risks of miscarriage and fetal malformation (47). More specifically, in the case of monotherapy there is a 7.5-17% risk, while a combination therapy is associated with a 25% risk (48).

The risks of chemotherapy are immediately correlated with gestational age. Exposure in weeks 1-2 (implantation phase) causes lethal mutations due to direct effect on stem cells, while exposure between weeks 2-8 (organogenesis) affects the heart, limbs and neural tube. Finally, exposure after week 8 endangers CNS development as well (49). Conversely, a recent study by Kohler on 21 pregnant women undergoing chemotherapy with cisplatin, did not show...
any malformations or incidents of perinatal morbidity (50). Another study by Kohler et al found that levels of platinum in umbilical cord blood and amniotic fluid were lower than those in maternal blood. The authors formulated the hypothesis that the placenta provides a possible filtration mechanism.

Data on neonatal outcomes, following chemotherapy during the later stages of gestation are scarce, especially regarding long term follow-up (51). One study by Amant et al on 70 cases followed-up for a median of 22.3 months, did not report adverse incidents regarding cognitive function. None of these cases included treatment in the first trimester after being exposed in utero to chemotherapy (52). Only 25 cases of neoadjuvant chemotherapy, during stage IB1, have been reported on. Again, there are few studies reporting on long-term follow-up (51, 53-56).

Endometrial cancer during pregnancy

Incidence of endometrial cancer in women below 40 years of age is very low. The majority of such patients are obese and diagnosed with grade 1, stage I disease, however women with low BMI<25 are more likely to have more aggressive tumours (clear cell or serous papillary) and/or more advanced stage (57). Gestation is a state of naturally increased progesterone, which acts protectively on the endometrium. It has been hypothesized that endometrial cancer during pregnancy might be due to an immature, progesterone-resistant endometrium. Malignancy may originate from immature basal cells, irresponsible to hormonal stimulation (58). The literature describes 31 cases of endometrial cancer stage I during pregnancy (59). Furthermore, fertility sparing progestin therapy (oral medroxyprogesterone or/and levonorgestrel intrauterine system) is quite common nowadays in young nullipara women. Park et al. showed that pre and post-treatment BMI<25 kg/m^2 can positively affect treatment response and recurrence rates (60).

Adnexal masses during pregnancy

Total incidence of adnexal masses during pregnancy is 1:500 gestations, while incidence of ovarian cancer is 1:10000-1:50000 gestations (61, 62). The adnexal mass is usually incidentally found during c-section (1/200-400 c-sections) (63). Of these, 33% are non-neoplastic (luteal cysts), 63% are benign (dermoid cyst 36%, serous cystadenoma 17%, mucinous cystadenoma 8%), 3% are malignant- low malignant potential and adenocarcinoma, while stromal or sex cord tumors comprise 1% (64). Germ cell tumors are more frequent in younger patients (65). However, incidence of epithelial ovarian cancer is increasing as maternal age is also on the rise. The diagnostic workup of ovarian cancer during gestation includes, pelvic U/S, MRI of the abdomen, chest X-ray, CA-125 (despite the fact that levels increase during pregnancy and normalize after 12 weeks gestation), AFP, beta-HCG, LDH, LFTs, urea, creatinine, while intraoperative biopsy also plays a significant role.

Tumors of low malignant potential and non-epithelial tumors (e.g. sex cord tumors) are usually diagnosed at an early stage (stage I) (66), where bilateral salpingo-oophorectomy, omentectomy and cytology at 16-18 weeks are recommended. Epithelial ovarian cancer at stage IA is treated with unilateral salpingo-oophorectomy, omentectomy and cytology at 16-18 weeks. Further treatment is not needed and gestation can proceed safely. With regards to epithelial ovarian cancer stages IC-IV, chemotherapy should be delayed until after 12-16 weeks gestation, while excision of corpus luteum should be delayed until after 14 weeks gestation (45, 67). If diagnosis is made during the first trimester, termination of pregnancy is recommended, followed by treatment, while if diagnosis is made during the second or third trimester chemotherapy is administered (platine-paclitaxel) initially (63). After fetal lung maturity is achieved, c-section is performed followed by surgical tumor debulking.

In case of suspected or confirmed cancer, surgical staging is recommended. Epithelial ovarian cancer standard treatment includes total hysterectomy, bilateral salpingo-oophorectomy, optimal debulking, followed by 6 cycles of combined carboplatin and paclitaxel (68). However, ovarian cancer during pregnancy may be treated more conservatively with ovarian cystectomy or unilateral salpingo-oophorectomy, including biopsies. Occasionally treatment will also include omentectomy, appendectomy, peritoneal biopsies, and pelvic and para-aortic lymphadenectomy (69). The aforementioned conservation of the contralateral ovary and uterus may be considered in stage IA, grade 1 to 2, following surgical staging, when histology is non-clear cell (70). Following the above, if the patient desires to continue the pregnancy, chemotherapy may be either delayed until after fetal lung maturity is achieved, and initiated after delivery, or administered neoadjuvantly (68, 70). With regards to stage III or IV, treatment varies by trimester of gestation. In the first trimester, if conservation of pregnancy prevents optimal debulking, the pregnancy must be terminated due to the risks of chemotherapy treatment. During the second trimester the optimal treatment is unilateral or bilateral oophorectomy, surgical excision of peritoneal tumors, omentectomy and pelvic and para-aortic lymph node sampling and appendectomy. The above must be followed by initiation of chemotherapy and term c-section and hysterectomy. Finally, in the third trimester, chemotherapy after c-section, hysterectomy and surgical staging, are indicated (70). Several studies have reported on delaying completion of debulking until a few weeks following vaginal delivery and administering cycles of platinum-based chemotherapy. Conversely, other authors recommend a c-section after fetal lung maturity is achieved (69).
Regarding neonatal outcomes, a number of studies have shown favourable outcomes following a treatment of combined of carboplatin and paclitaxel in pregnancy. As mentioned above, chemotherapy is not administered during the first trimester due to the risk associated with the treatment. More specifically, teratogenesis may occur in up to 25% of cases of carboplatin treatment, while that risk may be as low as 1.3% if treatment is in the second and third trimesters (71). The prognosis of ovarian cancer is not affected by gestation.

Conclusion
Cancer during pregnancy is a particularly challenging complication, and the optimal treatment remains elusive, as there are limited data from retrospective studies with small samples. As a result, it is crucial that data regarding survival of the women and long-term follow up of the children from different cancer centres and registries be shared. This need is dictated by the fact that the incidence of cancer during pregnancy will continue to rise as child-bearing age continues to increase.

Ethics Committee Approval: N/A.
Informed Consent: N/A.
Conflict of Interest: No conflict of interest is declared by the authors.
Financial Disclosure: The authors declared that this study received no financial support.

References